1. Academic Validation
  2. Peptide-to-Small Molecule: A Pharmacophore-Guided Small Molecule Lead Generation Strategy from High-Affinity Macrocyclic Peptides

Peptide-to-Small Molecule: A Pharmacophore-Guided Small Molecule Lead Generation Strategy from High-Affinity Macrocyclic Peptides

  • J Med Chem. 2022 Aug 11;65(15):10655-10673. doi: 10.1021/acs.jmedchem.2c00919.
Shuhei Yoshida 1 Shota Uehara 1 Noriyasu Kondo 1 Yu Takahashi 1 Shiho Yamamoto 1 Atsushi Kameda 1 Soichiro Kawagoe 1 Naoko Inoue 2 Masami Yamada 2 Norito Yoshimura 1 Yuki Tachibana 1
Affiliations

Affiliations

  • 1 Pharmaceutical Research Division, Shionogi Pharmaceutical Research Center, 3-1-1 Futaba-cho, Toyonaka, Osaka561-0825, Japan.
  • 2 PeptiDream Inc.3-25-23 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa210-0821, Japan.
Abstract

Recent technological innovations have led to the development of methods for the rapid identification of high-affinity macrocyclic Peptides for a wide range of targets; however, it is still challenging to achieve the desired activity and membrane permeability at the same time. Here, we propose a novel small molecule lead discovery strategy, ″Peptide-to-Small Molecule″, which is a combination of rapid identification of high-affinity macrocyclic Peptides via peptide display screening followed by pharmacophore-guided de novo design of small molecules, and demonstrate the applicability using nicotinamide N-methyltransferase (NNMT) as a target. Affinity selection by peptide display technology identified macrocyclic peptide 1 that exhibited good enzymatic inhibitory activity but no cell-based activity. Thereafter, a peptide pharmacophore-guided de novo design and further structure-based optimization resulted in highly potent and cell-active small molecule 14 (cell-free IC50 = 0.0011 μM, cell-based IC50 = 0.40 μM), indicating that this strategy could be a new option for drug discovery.

Figures
Products